ZEAL (ZEAL) News
Follow ZEAL (ZEAL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 27 public stories across 16 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
ZEAL Reports Nine-Month Revenue Increase of 22%
ZEAL says nine-month revenues increased 22% and that it has diversified into new markets.
EQUITY | Nov 04, 2026, 06:35 AM UTC
L
Zealand Pharma Reports Positive Phase 1 Topline Results for ZP9830
EQUITY | Oct 19, 2026, 05:03 AM UTC
M
Zealand Pharma Signs AI Protein Therapeutics Collaboration With Generate
The multi-target collaboration covers obesity and metabolic diseases. Generate will receive $30 million upfront and up to $35 million in early preclinical milestones, with up to approximately $1.2 billion in total milest
MNA | Oct 13, 2026, 08:38 PM UTC
M
Zealand Pharma strikes deal with Generate worth up to $1.2 billion
MNA | Oct 13, 2026, 08:27 PM UTC
M
Zealand Pharma Completes DKK 1.3B Buyback, Holds 7.37% Treasury
Zealand Pharma A/S completed its share buy-back program, repurchasing 4,408,500 shares for approximately DKK 1.3 billion. The company now holds 5,279,342 treasury shares, representing about 7.37% of its share capital. Th
EQUITY | Oct 05, 2026, 04:32 PM UTC
M
Zealand Pharma Shares Fall Amid Resurfaced Concerns Over Drug Trial Dropout Rates
Zealand Pharma's shares declined significantly as data revealed that nearly one in five patients discontinued the late-stage survodutide trial for obesity due to gastrointestinal side effects. These high dropout rates ar
EQUITY | Oct 01, 2026, 11:16 AM UTC
M
Zealand Pharma Shares Fall on Obesity Drug Trial Dropout Data
Zealand Pharma shares fell 8.5% after German partner Boehringer Ingelheim reported late-stage clinical trial results for an obesity drug candidate licensed from the Danish biotech, showing a nearly one-fifth patient drop
EQUITY | Oct 01, 2026, 09:49 AM UTC
H
Zealand Pharma: Survodutide Shows 13.1% Weight Loss in Obesity/Diabetes Trial
Boehringer Ingelheim's survodutide achieved up to 13.1% weight loss and significant improvements in glycemic control during a Phase III trial involving patients with obesity and type 2 diabetes. The results were announce
EQUITY | Oct 01, 2026, 07:32 AM UTC
L
Zealand Pharma A/S (ZEAL) Publishes Phase 2 Petrelintide Data; To Present at EASD
Zealand Pharma A/S said Phase 2 ZUPREME-1 results for petrelintide were published in The Lancet Diabetes & Endocrinology and will be presented at EASD 2026 on Sept. 30 at 3:30pm CEST.Material DetailsContext by AI Analyst
NEWS | Sep 29, 2026, 10:08 PM UTC
L
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
Press release — No. 18 / 2026Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & EndocrinologyCopenhage
NEWS | Sep 29, 2026, 10:08 PM UTC
L
Zealand Pharma A/S (ZEAL) Updates Week 39 Buyback; Treasury Shares Now ~6.72%
Zealand Pharma reported week 39 transactions under its buy-back program of up to DKK 1.3B. It now holds 4,810,842 treasury shares, about 6.72% of its 71,610,005 share capital.Material DetailsContext by AI AnalystThis is
EQUITY | Sep 28, 2026, 03:01 PM UTC
L
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
Company announcement No. 50 / 2026Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)Copenhagen, Denmark, September 28, 2026 — Zealand Pharma A/S ("the Company" or “Zealand Pharma”) NASDAQ:ZEA
NEWS | Sep 28, 2026, 03:01 PM UTC
M
Zealand Pharma expects Phase 3 Zupreme trials to enroll ~7,000
Zealand Pharma said its Phase 3 Zupreme trials are expected to enroll about 7,000 participants.
EQUITY | Sep 22, 2026, 03:25 PM UTC
M
Zealand Pharma starts registrational Phase 3 ZUPREME for petrelintide
Zealand Pharma said it has initiated the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity.
EQUITY | Sep 22, 2026, 03:01 PM UTC
M
Zealand Pharma Zeydovio gets positive EU panel opinion
Zealand Pharma said the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of its short bowel syndrome drug candidate Zeydovio (OMXCOP: ZEAL).
REGULATION | Sep 18, 2026, 12:23 PM UTC
M
Zealand Pharma wins positive CHMP opinion for Zeydovio in short bowel syndrome
CHMP issued a positive opinion recommending EU marketing authorization for Zeydovio (glepaglutide) for adults with short bowel syndrome; European Commission decision expected in ~67 days.
REGULATION | Sep 18, 2026, 10:13 AM UTC
M
Zealand Pharma gets positive CHMP opinion for Zeydovio in short bowel syndrome
Zealand Pharma says the CHMP has issued a positive opinion for Zeydovio (glepaglutide) for treating short bowel syndrome.
REGULATION | Sep 18, 2026, 10:12 AM UTC
M
Zealand Pharma receives positive CHMP opinion for Zeydovio
TradingView News reports Zealand Pharma has received a positive CHMP opinion for Zeydovio for the treatment of short bowel syndrome.
REGULATION | Sep 18, 2026, 10:12 AM UTC
L
Zealand Pharma increases share capital after employee warrant exercise
Zealand Pharma said it increased its share capital following the exercise of employee warrants. The announcement is numbered 47/2026 and dated September 10, 2026.
EQUITY | Sep 10, 2026, 03:01 PM UTC
L
Zealand Pharma to participate in Morgan Stanley 24th Global Healthcare Conference
Zealand Pharma A/S said it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, per a press release dated September 9, 2026 from Copenhagen, Denmark.
EQUITY | Sep 09, 2026, 03:01 PM UTC
L
Zealand Pharma reports share buy-back transactions for week 36, 2026
Zealand Pharma A/S said it completed transactions under its share buy-back program for week 36, 2026. The company issued Company announcement No. 46 / 2026 from Copenhagen, Denmark on September 7, 2026.
EQUITY | Sep 07, 2026, 03:07 PM UTC
L
Zealand Pharma issues correction on share buy-back program trades (week 35)
Zealand Pharma A/S (NASDAQ:ZEAL) issued a company announcement correction covering transactions related to its share buy-back program for week 35, 2026.
EQUITY | Sep 02, 2026, 03:07 PM UTC
L
Zealand Pharma share buy-back transactions reported for week 35
Zealand Pharma reported transactions related to its share buy-back program for week 35, 2026.
EQUITY | Aug 31, 2026, 03:07 PM UTC
L
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely asso
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
EQUITY | Aug 28, 2026, 08:07 PM UTC
H
Zealand Pharma Rethinks Obesity Strategy
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based dr
EQUITY | Jun 19, 2026, 07:45 AM UTC
H
Zealand Pharma Tumbles
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based dr
EQUITY | Jun 19, 2026, 05:35 AM UTC